Warning: The NCBI web site requires JavaScript to function. more...
Are triple-negative tumours and basal-like breast cancer synonymous?
Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS.
Breast Cancer Res. 2007;9(6):404; author reply 405. No abstract available.
Related citations
[Biological features of breast cancer in patients under 35].
Damenia AO, Turkevich EA, Semiglazov VF, Kochetova IA, Gurbanov SS, Bit-Sava EM, Efimenko AV.
Vopr Onkol. 2007;53(6):674-6. Russian.
How basal are triple-negative breast cancers?
Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D.
Int J Cancer. 2008 Jul 1;123(1):236-40.
Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.
Breast Cancer. 2009;16(4):260-7. Epub 2009 Aug 22.
High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
Saatee S, Afrakhteh M, Sadrolhefazi B.
Breast J. 2006 Sep-Oct;12(5):499-501. No abstract available.
Breast density influences tumor subtypes and tumor aggressiveness.
Kerlikowske K, Phipps AI.
J Natl Cancer Inst. 2011 Aug 3;103(15):1143-5. Epub 2011 Jul 27. No abstract available.
Breast cancer heterogeneity: a mixture of at least two main types?
Anderson WF, Matsuno R.
J Natl Cancer Inst. 2006 Jul 19;98(14):948-51. No abstract available.
JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.
Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, O'Malley FP, Egan SE, Andrulis IL.
Breast Cancer Res Treat. 2008 Oct;111(3):439-48. Epub 2007 Nov 8.
Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J.
Eur J Clin Invest. 2008 Jun;38(6):438-46. Epub 2008 Apr 30.
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
Am J Surg Pathol. 2008 Apr;32(4):544-52.
Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers?
Pignol JP, Rakovitch E, Olivotto IA.
J Clin Oncol. 2011 Jul 20;29(21):2841-3. Epub 2011 Jun 13. No abstract available.
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.
Clin Cancer Res. 2008 Mar 1;14(5):1368-76.
[Occult multicentric breast cancer].
Vtorushin SV, Zab'ialova MV, Glushchenko SA, Perel'muter VM, Slonimskaia EM.
Vopr Onkol. 2009;55(1):38-41. Russian.
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.
J Clin Oncol. 2008 Mar 20;26(9):1419-26. Epub 2008 Feb 19.
[Triple-negative breast cancer--towards a new entity].
Miron L, Marinca A, Marinca M, Miron I.
Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):51-8. Romanian.
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO.
Clin Cancer Res. 2009 Apr 1;15(7):2302-10. Epub 2009 Mar 24.
[Current aspects in histopathological assessment of breast cancer].
Sastre X.
Bull Cancer. 1997 Jan;84(1):65-8. French.
Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY.
Jpn J Clin Oncol. 2011 Jul;41(7):854-66.
Factors predictive of response to hormone therapy in breast cancer.
Rastelli F, Crispino S.
Tumori. 2008 May-Jun;94(3):370-83. Review.
Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T.
J Surg Oncol. 2008 Jan 1;97(1):30-4.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on